“This is a landmark approval, making the UK the first country in Europe to approve Wegovy\u00ae pill,\u201d said Emil Kongsh\u00f8j Larsen, executive vice president, International Operations, Novo Nordisk. “Today, around 15 million people in the UK are living with obesity, yet only a small proportion of them have access to treatment, and we hope this approval supports increasing access to obesity care in the UK. With the introduction of this option for weight management, we have an opportunity to support many more eligible patients. Most importantly, this gives patients another option – one that may fit their lives and help them reach their health goals.\u201d<\/p>\n
Novo Nordisk has previously announced plans to launch Wegovy\u00ae\u00a0pill in select markets in the second half of 2026.\u00a0The MHRA is the third regulatory authority to license the medicine, after the U.S. Food and Drug Administration (FDA) and the United Arab Emirates, Emirates Drug Establishment (EDE).\u00a0<\/p>\n
OASIS 4 results<\/p>\n
The OASIS 4 trial included two pre-specified analyses: an on-treatment analysis assessing outcomes if all participants remained on treatment, and a treatment policy analysis reflecting outcomes regardless of treatment discontinuation.<\/p>\n
About obesity<\/p>\n
Obesity is a complex, chronic disease affecting around 15 million people in the UK, with 71% of adults in the UK\u00a0projected to be living with obesity or overweight by 2040. The condition requires long-term management. Treatment options should be individualised, with decisions about pharmacotherapy made jointly by healthcare professionals and patients.<\/p>\n
About the OASIS 4 trial<\/p>\n
OASIS 4 was a randomised, double-blind, placebo-controlled phase 3 clinical trial evaluating the efficacy and safety of semaglutide 25mg tablets in adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbidity, without type 2 diabetes. The trial had two co\u2011primary endpoints: change in body weight (%) and the proportion achieving \u22655% weight loss at week 64. 307 participants were randomised 2:1 to receive semaglutide 25mg tablets or placebo once daily for 64 weeks in addition to lifestyle interventions. All participants received advice on diet and physical activity, including a daily 500 kcal deficit and a structured exercise regimen. The safety and tolerability profile for semaglutide 25 mg tablets in OASIS 4 was consistent with that observed for semaglutide injection. The most common adverse events were gastrointestinal, and the majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.<\/p>\n
About Novo Nordisk\u00a0<\/p>\n
Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases – from diabetes and obesity to rare blood and endocrine disorders – by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and\u00a0ultimately cure\u00a0disease. We are committed to long-term, responsible business practices that deliver financial,\u00a0social\u00a0and environmental value. Headquartered in Denmark and\u00a0operating\u00a0in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in\u00a0roughly 170\u00a0countries. For more information, visit\u00a0novonordisk.com<\/a>,\u00a0Facebook<\/a>,\u00a0Instagram<\/a>,\u00a0X<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0YouTube<\/a>.\u00a0<\/p>\n Contacts\u00a0for further information<\/p>\n Attachment<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/1781194332_629_Novo-Nordisk-A-S.png\"\/)
<\/p>\n","protected":false},"excerpt":{"rendered":"Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults…\n","protected":false},"author":2,"featured_media":105713,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[27734,9765,2483,6916,3335,216,5691,3845,272,4033,689,53769,1967,9317,1910,280],"class_list":["post-105712","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-approved","tag-becomes","tag-daily","tag-first","tag-glp-1","tag-in","tag-nordisk","tag-novo","tag-novo-nordisk","tag-pill","tag-semaglutide","tag-tablets","tag-the","tag-uk","tag-wegovy","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116732359405289777","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/105712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=105712"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/105712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/105713"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=105712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=105712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=105712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}